STAT+: Alzheimer’s scientists critique Cassava Sciences’ study results — overblown, inappropriate, uninterpretable
Independent researchers are expressing doubts about the purported benefits of an experimental treatment for Alzheimer’s from Cassava Sciences.
The company said Thursday that a preliminary analysis of a small clinical trial showed its drug, called simufilam, improved the cognition of patients with Alzheimer’s disease — a benefit that no other treatment for Alzheimer’s has ever shown.
Continue to STAT+ to read the full story…
